Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.
about
Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse modelsThe involvement of secondary neuronal damage in the development of neuropsychiatric disorders following brain insults.Synergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells.High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataHistone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling.Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells.γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity.(+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activationTumor necrosis factor-related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotypeAntitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cellsInhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migrationAutocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell functionMorin (3,5,7,2',4'-Pentahydroxyflavone) abolishes nuclear factor-kappaB activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-kappaB-regulated gene expression and up-regulation of apoptosisTrichostatin A enhances proliferation and migration of vascular smooth muscle cells by downregulating thioredoxin 1.Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.Inhibition of histone deacetylases in inflammatory bowel diseases.HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.Panobinostat for the treatment of multiple myeloma.Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases.Epigenetic regulation of mmp-9 gene expression.MicroRNA-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer.Selective, potent blockade of the IRE1 and ATF6 pathways by 4-phenylbutyric acid analogues.The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γAntitumor effect of pretreatment for colon cancer cells with hyperthermia plus geranylgeranylacetone in experimental metastasis models and a subcutaneous tumor model of colon cancer in mice.Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastomaIncreased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA.Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.Histone deacetylase inhibitors and periodontal bone loss.Opposite effects of Trichostatin A on activation of mast cells by different stimulants.Histone deacetylase inhibitors block nuclear factor-κB-dependent transcription by interfering with RNA polymerase II recruitment.Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line.Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53.Epigenetic modulation of chronic anxiety and pain by histone deacetylation.Host modulation therapy with anti-inflammatory agents.Effect of a Histone Deacetylases Inhibitor of IL-18 and TNF-Alpha Secretion in Vitro.
P2860
Q27310013-A38E4773-F562-432C-94C7-C29AA422DCA3Q30441452-15CFEF60-49B7-4739-B225-E385460E5E28Q30541284-31875FCA-3ABC-47EA-88E5-35A686B22ED9Q30884835-9B257310-D54C-45E3-9B07-6BF87A922EF3Q30936712-840958C2-FB45-43F6-A634-9BFFE9328634Q33614697-C927A427-8A9E-44E7-81E9-BCC3C2D8074CQ34173886-77DB4BF0-2BBC-4216-B4F3-49AD40549C75Q34236653-62BE59DE-777E-4DBA-8BFD-A9CE661EF618Q34588342-1A5895FA-5F7A-4719-8F72-224CB9910B02Q35099825-775CECEE-42FD-43A6-9854-3A3715E67B36Q36058434-979A3FDA-234B-4FD0-B104-5B914E7F5360Q36094595-FCDC1736-20E0-483A-BD67-51FB6FC6B2FEQ36302249-0C0C1909-0F91-4334-A4AF-BB5039B9A6F5Q36608727-F87CC93F-7737-46BF-8F8B-3F81B1B55C0BQ36986304-59335DED-AED4-4873-9EF9-8D75BE40BB0FQ37144949-EDABA4B2-DC1F-4CF9-AEF7-1516D52EC454Q37338875-366114CD-F72A-4C16-9620-020858535BA6Q37467846-0EE05670-2BE8-443B-9E2C-6636DB56152BQ37626634-23F87011-BDED-42BA-94D3-BE6C635FE8ECQ37848684-77B3C65E-96AE-4AB6-A3A9-578822D622A4Q37949185-46FC5A9D-EF5E-4F8F-8F63-95351B329BC0Q37992104-CA982364-C337-42E8-8A0A-B70722D5089BQ38008692-127EFA07-98B2-45FD-8EE0-F2D1F336153DQ38062851-4F34A34A-9661-41AD-BF52-0882B1BF8DD5Q38904555-A7AD9C5E-E98D-45D3-8FE3-2D843F56441CQ39123489-343F9F5D-6ED3-41E3-A416-04AE1E9BBC6FQ39339685-C74B065F-4AB9-4EF6-8BD6-149750564F69Q39865723-FC489D35-8D37-425D-BBFC-2D942CACE7CDQ41728555-9230B903-8602-4E60-BFDD-57C93552883AQ41881419-F97DA328-004A-4747-8B9F-2EB6E97E3271Q42504159-94329493-1CC3-494C-B1AC-770BA544D4DCQ42730771-50CA9B37-8C8B-4BC2-9930-F363B18EA4BAQ43108191-B77D38D5-04B1-4DF9-909B-ACAE2DE72154Q45820993-6F80EA7C-B119-4BB4-926B-E7B72BF0D2C3Q45922582-6D28C922-D020-449A-92D3-D510E4F121A8Q47136872-F8856577-1158-44C4-AFC8-77160C4CE2B0Q48494798-FC18FF6E-B194-405D-896D-6F93616F2F8DQ48585276-8E8DE068-BE70-4BE1-A6B1-681ED0A8295CQ52727010-63DFE832-F865-46EB-B34C-DC896CA41E32
P2860
Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Suberoylanilide hydroxamic aci ...... lear factor-kappaB activation.
@en
type
label
Suberoylanilide hydroxamic aci ...... lear factor-kappaB activation.
@en
prefLabel
Suberoylanilide hydroxamic aci ...... lear factor-kappaB activation.
@en
P2093
P2860
P356
P1476
Suberoylanilide hydroxamic aci ...... lear factor-kappaB activation.
@en
P2093
Bharat B Aggarwal
Haruyo Ichikawa
Yasunari Takada
P2860
P304
P356
10.1074/JBC.M507213200
P407
P577
2005-12-23T00:00:00Z